The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer of the Company. He succeeds Matthias Gaertner, who will remain in office until December 31, 2025. This leadership transition comes at a critical juncture for Medios as it seeks to strengthen its position in the European Specialty Pharma sector.
Thomas Meier brings substantial international pharmaceutical experience to his new role, having served as CEO of Swiss CDMO company Bachem Holding AG since 2020. Prior to this leadership position, he was Chief Operations Officer on the Executive Board of Bachem and worked as Head of Manufacturing at Peninsula Laboratories in San Carlos, California, from 2001 to 2004. His background in both European and American pharmaceutical manufacturing provides valuable cross-continental perspective for Medios' expansion plans.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment. "With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth. We warmly welcome him and are convinced that his entrepreneurial spirit, expertise and leadership will contribute significantly to achieving our ambitious goals and sustainably increasing value for shareholders, partners, and customers." Samson also acknowledged outgoing CEO Matthias Gaertner's decade of service, noting his "decisive influence on the growth and success of Medios."
Thomas Meier expressed enthusiasm for his new responsibilities, stating, "I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios' position in the European Specialty Pharma market." This commitment to strategic continuity while pursuing growth reflects the company's balanced approach to leadership transition.
The appointment occurs as Medios prepares for several important financial events in the 2025 fiscal year, including the Quarterly Statement as of September 30, 2025 on November 11, participation in the mwb inspired Conference in Hamburg on November 12, and the Berenberg European Conference at Fairmont Windsor Park in Great Britain on December 4. These events will provide early opportunities for Meier to engage with investors and stakeholders as he prepares to assume leadership. Medios maintains its corporate information at https://www.medios.group and provides additional resources on individualized medicine at https://app.medios.group/en/individualizedmedicine.
For HR vendors serving the pharmaceutical and healthcare sectors, this leadership change at Medios signals potential shifts in procurement strategies, talent management needs, and partnership opportunities. Meier's international background suggests Medios may pursue more cross-border operations, creating demand for HR solutions that support global workforce management, compliance across European markets, and specialized recruitment for pharmaceutical expertise. The emphasis on "capital-efficient, profitable growth" indicates a continued focus on operational excellence that could drive interest in HR technologies supporting productivity and cost management. As Medios expands its position in the European Specialty Pharma market, vendors offering solutions for specialized talent acquisition, compliance training for pharmaceutical regulations, and performance management systems tailored to research and manufacturing environments may find increased opportunities. The planned stakeholder engagements throughout 2025 provide a timeline for vendors to align their outreach with Medios' strategic communications, while the company's focus on individualized medicine suggests growing needs for HR support in specialized clinical and research roles.
